<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011974'>Myelofibrosis</z:hpo> occurs in various hematologic <z:hpo ids='HP_0002664'>neoplasias</z:hpo>, including <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), with a relatively low incidence </plain></SENT>
<SENT sid="1" pm="."><plain>To gain insight into the clinical and cytogenetic implications of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients in whom <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> develops, statistical analysis was done on 82 primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with successful cytogenetic results </plain></SENT>
<SENT sid="2" pm="."><plain>Seven patients had <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> during the course of the disease (8.5%, Group I), 34 had abnormal karyotypes without <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (41.5%, Group II), and the other 41 had abnormal karyotypes without <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (50%, Group III) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients except one with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> had cytogenetic abnormalities, and four of them had multiple chromosome abnormalities </plain></SENT>
<SENT sid="4" pm="."><plain>In univariant analysis, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> showed no significant differences in age, sex, or peripheral blood data </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, patients with chromosome abnormalities evolved into <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> with a high incidence compared with those with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotypes (14.6% versus 2.4%, P = 0.054) </plain></SENT>
<SENT sid="6" pm="."><plain>The occurrence of <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> was higher during the first 6 months after the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in the next 6 months (6.1% versus 0%, P = 0.045) </plain></SENT>
<SENT sid="7" pm="."><plain>Most of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients survived for less than 10 months after <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> was evident </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, survival was significantly shorter in Group I compared with Groups II (P less than 0.05) and III (P less than 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients in whom <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> developed, some were associated with <z:hpo ids='HP_0011009'>acute</z:hpo> megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, indicating a <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of clinical features in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
</text></document>